For the quarter ending 2025-09-30, RPTX made $11,620K in revenue. $3,280K in net income. Net profit margin of 28.23%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Collaboration agreements | 11,620 | 250 | - | 13,369* |
| Research and development, net of tax credits | 7,502 | 14,283 | 20,270 | -9,370* |
| General and administrative | 4,548 | 6,029 | 7,652 | 10,348* |
| Restructuring | 1,826 | 3,384 | 3,265 | -3,202* |
| Total operating expenses | 13,876 | 23,696 | 31,187 | -2,224* |
| Gain on sale of technology and other assets | 130 | 5,666 | - | - |
| Gain on termination of collaboration agreement | 3,257 | - | - | - |
| Income (gain) from operations | 1,131 | -17,780 | -31,187 | 15,593* |
| Other expense, net | - | 18 | 22 | -11* |
| Realized and unrealized (gain) loss on foreign exchange | -41 | 66 | -2 | 55* |
| Interest income | 2,224 | 1,236 | 1,538 | 2,855* |
| Other income (expense), net | 89 | - | - | - |
| Total other income, net | 2,272 | 1,284 | 1,514 | 2,921* |
| Income (gain) before income taxes | 3,403 | -16,496 | -29,673 | 18,514* |
| Income tax expense | 145 | 248 | 370 | -15* |
| Net income (gain) | 3,258 | -16,744 | -30,043 | 18,529* |
| Unrealized loss on available-for-sale marketable securities | - | 0 | - | - |
| Unrealized loss (gain) on available-for-sale marketable securities | 22 | -17 | -45 | -796 |
| Total other comprehensive income (gain) | 22 | -17 | -45 | -796* |
| Comprehensive income (gain) | 3,280 | -16,761 | -30,088 | 17,733 |
| Basic EPS | 0.08 | -0.39 | -0.71 | 0.419 |
| Diluted EPS | 0.08 | -0.39 | -0.71 | 0.419 |
| Basic Average Shares | 42,965,529 | 42,921,936 | 42,591,730 | 42,369,553 |
| Diluted Average Shares | 43,051,934 | 42,921,936 | 42,591,730 | 42,369,553 |
Repare Therapeutics Inc. (RPTX)
Repare Therapeutics Inc. (RPTX)